BACKGROUND: Studies of biomarkers of hypothalamic-pituitary-adrenal activity indicate that psychotic disorders are associated with elevated cortisol. This study examined cortisol levels in healthy control subjects and individuals who met clinical high-risk (CHR) criteria for psychosis. It was hypothesized that cortisol levels would be 1) elevated in the CHR group relative to control subjects, 2) positively correlated with symptom severity, and 3) most elevated in CHR patients who transition to psychotic level severity. METHODS: Baseline assessments were conducted at eight centers in the North American Prodrome Longitudinal Study. The present CHR sample included 256 individuals meeting the Scale for Prodromal Symptoms criteria and 141 control subjects, all of whom underwent baseline assessment and measurement of salivary cortisol. RESULTS: Consistent with previous reports, there was an effect of age on cortisol, with increases through the adolescent/early adult years. Analysis of covariance showed a main effect of diagnostic group, with the CHR group showing higher cortisol. There were modest, positive correlations of cortisol with baseline symptom severity, and analysis of covariance revealed higher baseline cortisol in those who transitioned to psychotic level symptoms when compared with healthy control subjects and CHR subjects who remitted. CONCLUSIONS: The present findings add to accumulating evidence of heightened cortisol secretion in CHR individuals. The findings also indicate nonspecific associations between cortisol levels and symptom severity, as well as symptom progression. The role of hypothalamic-pituitary-adrenal activity in prediction of conversion to psychosis and its relation with other biomarkers of risk should receive attention in future research.
BACKGROUND: Studies of biomarkers of hypothalamic-pituitary-adrenal activity indicate that psychotic disorders are associated with elevated cortisol. This study examined cortisol levels in healthy control subjects and individuals who met clinical high-risk (CHR) criteria for psychosis. It was hypothesized that cortisol levels would be 1) elevated in the CHR group relative to control subjects, 2) positively correlated with symptom severity, and 3) most elevated in CHR patients who transition to psychotic level severity. METHODS: Baseline assessments were conducted at eight centers in the North American Prodrome Longitudinal Study. The present CHR sample included 256 individuals meeting the Scale for Prodromal Symptoms criteria and 141 control subjects, all of whom underwent baseline assessment and measurement of salivary cortisol. RESULTS: Consistent with previous reports, there was an effect of age on cortisol, with increases through the adolescent/early adult years. Analysis of covariance showed a main effect of diagnostic group, with the CHR group showing higher cortisol. There were modest, positive correlations of cortisol with baseline symptom severity, and analysis of covariance revealed higher baseline cortisol in those who transitioned to psychotic level symptoms when compared with healthy control subjects and CHR subjects who remitted. CONCLUSIONS: The present findings add to accumulating evidence of heightened cortisol secretion in CHR individuals. The findings also indicate nonspecific associations between cortisol levels and symptom severity, as well as symptom progression. The role of hypothalamic-pituitary-adrenal activity in prediction of conversion to psychosis and its relation with other biomarkers of risk should receive attention in future research.
Authors: Elaine F Walker; Patricia A Brennan; Michelle Esterberg; Joy Brasfield; Brad Pearce; Michael T Compton Journal: J Abnorm Psychol Date: 2010-05
Authors: Doron Gothelf; Fumiko Hoeft; Takefumi Ueno; Lisa Sugiura; Agatha D Lee; Paul Thompson; Allan L Reiss Journal: J Psychiatr Res Date: 2011-03 Impact factor: 4.791
Authors: Belinda Garner; Christina Phassouliotis; Lisa J Phillips; Connie Markulev; Felicity Butselaar; Sarah Bendall; Yang Yun; Patrick D McGorry Journal: J Psychiatr Res Date: 2010-07-08 Impact factor: 4.791
Authors: Nils Eiel Steen; Martin Tesli; Anna K Kähler; Paal Methlie; Sigrun Hope; Elizabeth A Barrett; Sara Larsson; Erlend Mork; Kristian Løvås; Jan Ivar Røssberg; Ingrid Agartz; Ingrid Melle; Srdjan Djurovic; Steinar Lorentzen; Jens P Berg; Ole A Andreassen Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2010-08-25 Impact factor: 5.067
Authors: Valeria Mondelli; Carmine M Pariante; Serena Navari; Monica Aas; Alessandro D'Albenzio; Marta Di Forti; Rowena Handley; Nilay Hepgul; Tiago Reis Marques; Heather Taylor; Andrew S Papadopoulos; Katherine J Aitchison; Robin M Murray; Paola Dazzan Journal: Schizophr Res Date: 2010-01-13 Impact factor: 4.939
Authors: Joya N Hampton; Hanan D Trotman; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Ming T Tsuang; Diana O Perkins; Larry J Seidman; Scott W Woods; Elaine F Walker Journal: Stress Health Date: 2018-06-28 Impact factor: 3.519
Authors: Danielle M Moskow; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Robert Heinssen; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Tyrone D Cannon; Scott W Woods; Elaine F Walker Journal: Schizophr Res Date: 2016-02-20 Impact factor: 4.939
Authors: Brandee Feola; Kristan Armstrong; Neil D Woodward; Stephan Heckers; Jennifer Urbano Blackford Journal: Psychiatry Res Date: 2019-03-11 Impact factor: 3.222